These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32629127)

  • 41. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
    Bedossa P; Patel K
    Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
    Harrison SA; Rossi SJ; Paredes AH; Trotter JF; Bashir MR; Guy CD; Banerjee R; Jaros MJ; Owers S; Baxter BA; Ling L; DePaoli AM
    Hepatology; 2020 Apr; 71(4):1198-1212. PubMed ID: 30805949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis.
    Sanyal AJ; Shankar SS; Yates KP; Bolognese J; Daly E; Dehn CA; Neuschwander-Tetri B; Kowdley K; Vuppalanchi R; Behling C; Tonascia J; Samir A; Sirlin C; Sherlock SP; Fowler K; Heymann H; Kamphaus TN; Loomba R; Calle RA
    Nat Med; 2023 Oct; 29(10):2656-2664. PubMed ID: 37679433
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.
    Decaris ML; Li KW; Emson CL; Gatmaitan M; Liu S; Wang Y; Nyangau E; Colangelo M; Angel TE; Beysen C; Cui J; Hernandez C; Lazaro L; Brenner DA; Turner SM; Hellerstein MK; Loomba R
    Hepatology; 2017 Jan; 65(1):78-88. PubMed ID: 27706836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.
    Simbrunner B; Marculescu R; Scheiner B; Schwabl P; Bucsics T; Stadlmann A; Bauer DJM; Paternostro R; Eigenbauer E; Pinter M; Stättermayer AF; Trauner M; Mandorfer M; Reiberger T
    Liver Int; 2020 Jul; 40(7):1713-1724. PubMed ID: 32358998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P; Patel J; Ingle M; Sawant P
    Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity.
    Fagan KJ; Pretorius CJ; Horsfall LU; Irvine KM; Wilgen U; Choi K; Fletcher LM; Tate J; Melino M; Nusrat S; Miller GC; Clouston AD; Ballard E; O'Rourke P; Lampe G; Ungerer JP; Powell EE
    Liver Int; 2015 Jun; 35(6):1673-81. PubMed ID: 25495373
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
    Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
    Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
    Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
    Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years.
    Kawanaka M; Nishino K; Morimoto Y; Ishii K; Tanikawa T; Urata N; Suehiro M; Sasai T; Haruma K; Kawamoto H
    Intern Med; 2021 May; 60(9):1397-1401. PubMed ID: 33281161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.